ConductScience.org, home

Paper25947367

Impact of special patient populations on the pharmacokinetics of echinocandins.

Muilwijk EW and 6 others. Expert Rev Anti Infect Ther, 2015. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Impact of special patient populations on the pharmacokinetics of echinocandins. Papers, record 25947367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25947367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of special patient populations on the pharmacokinetics of echinocandins.
PubMed
Journal
Expert Rev Anti Infect Ther
PubMed
Year
2015
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.51
iCite
Revised in PubMed
2018-12-02
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muilwijk EWEline W
2Lempers VJVincent J C
3Burger DMDavid M
4Warris AAdilia
5Pickkers PPeter
6Aarnoutse RERob E
7Brüggemann RJRoger J M

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antifungal AgentsMajor topic
EchinocandinsMajor topic
LipopeptidesMajor topic
Adolescent
Adult
Anidulafungin
Candida
Caspofungin
Child
Critical Illness
Drug Interactions
Hematologic Diseases
Humans
Infant, Newborn
Kidney
Liver
Micafungin
Microbial Sensitivity Tests
Obesity

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
40468532Prevalence of OATP1B-Mediated Drug-Drug Interactions in an Academic Medical Center.Clin Transl Sci2025https://conductscience.org/library/papers/40468532PubMed
38526051Updated antimicrobial dosing recommendations for obese patients.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/38526051PubMed
36408257
The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations.
Front Pharmacol2022https://conductscience.org/library/papers/36408257PubMed
35296203Echinocandins - structure, mechanism of action and use in antifungal therapy.J Enzyme Inhib Med Chem2022https://conductscience.org/library/papers/35296203PubMed
33404989Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis.Pharm Res2021https://conductscience.org/library/papers/33404989PubMed
33384549Invasive fungal infection before and after liver transplantation.World J Gastroenterol2020https://conductscience.org/library/papers/33384549PubMed
33333012Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.Lancet Infect Dis2021https://conductscience.org/library/papers/33333012PubMed
32672361Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.J Clin Pharm Ther2020https://conductscience.org/library/papers/32672361PubMed
32667449Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study.Rev Bras Ter Intensiva2020https://conductscience.org/library/papers/32667449PubMed
30150463Caspofungin Modulates Ryanodine Receptor-Mediated Calcium Release in Human Cardiac Myocytes.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/30150463PubMed
29881298Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.Infect Drug Resist2018https://conductscience.org/library/papers/29881298PubMed
29849129Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.Acta Pharmacol Sin2018https://conductscience.org/library/papers/29849129PubMed
29551905Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis.Infect Drug Resist2018https://conductscience.org/library/papers/29551905PubMed
27820668New facets of antifungal therapy.Virulence2017https://conductscience.org/library/papers/27820668PubMed
27001813Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/27001813PubMed
26503647Cardiac Effects of Echinocandins in Endotoxemic Rats.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/26503647PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25947367

GET https://conductscience.org/api/papers/v1/25947367/authors